RecruitingPhase 4NCT06941870

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

Prospective Interventional Study of Effectiveness of Efanesoctocog Alfa Prophylaxis on Synovial Hypertrophy in Patients With Hemophilia A

Sponsor

Sanofi

Enrollment

35 participants

Start Date

Sep 23, 2025

Study Type

INTERVENTIONAL

Conditions

Factor VIII Deficiency

Summary

The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A. The study duration for each participant is approximately 12 months.

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Efanesoctocog alfa for people with factor viii deficiency. The study is currently recruiting participants at 13 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEfanesoctocog alfa

Pharmaceutical form:Lyophilized powder in a sterile vial that requires reconstitution with sterile water for injection (diluent)-Route of administration:Intravenous

Locations(13)

Orthopedic Institute for Children- Site Number : 8400009

Los Angeles, California, United States

Innovative Hematology, Inc.- Site Number : 8400006

Indianapolis, Indiana, United States

University of Iowa- Site Number : 8400004

Iowa City, Iowa, United States

Ohio State University Hospital East- Site Number : 8400001

Columbus, Ohio, United States

Investigational Site Number : 1240003

Hamilton, Ontario, Canada

Investigational Site Number : 1240004

Hamilton, Ontario, Canada

Investigational Site Number : 3920003

Kawasaki, Kanagawa, Japan

Investigational Site Number : 3920002

Hiroshima, Japan

Investigational Site Number : 3920001

Saitama, Japan

Investigational Site Number : 3920004

Tokyo, Japan

Investigational Site Number : 1580003

Kaohsiung City, Taiwan

Investigational Site Number : 1580001

Taichung, Taiwan

Investigational Site Number : 1580002

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06941870

Related Trials

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

NCT0439862871 locations

The European Paediatric Network for Haemophilia Management ( PedNet Registry)

NCT0297911939 locations